Sigma-Aldrich has entered into an agreement with Pfizer under which it will sell approximately 100 Pfizer-developed small molecule compounds to life-science researchers.
The compounds will be used for target characterisation, assay development, screening and in-vivo animal-model applications.
Under the agreement, the compounds, which include patented and approved drug molecules such as atorvastatin, sildenafil and celecoxib, will be made available to the research community while still on patent, in some cases for the first time.
The inclusion of these Pfizer compounds provides authentic material that will help advance researchers' understanding of biological systems.
The Pfizer compounds will be sold through Sigma-Aldrich as in-stock, pre-packaged items and, upon request, in bulk.
They will also be mapped to genes, associated pathways and interactors via Sigma-Aldrich's online search platform, 'Your favorite gene powered by ingenuity'.
Sigma-Aldrich expects to add further Pfizer compounds on a regular basis.
